Adjuvant compositions
AssigneeNovarttis Vaccines and Diagnostics, Inc.
InventorsDerek O'Hagan, Nicholas Valiante
Life of this patent
Estimating the term…
Abstract
Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.
Claims75
A composition comprising:
- (1) a type 1 interferon inducer;
- and (2) an antigen delivery system and/or an immunostimulatory molecule,
- wherein the composition is capable of increasing the immune response to a coadministered antigen as compared to delivery of the antigen and type 1 interferon inducer alone without the antigen delivery system and/or the immunostimulatory molecule.
A composition comprising a dsRNA, a submicron oil-in-water emulsion and a selected antigen, wherein the composition is capable of increasing the immune response to the antigen as compared to delivery of the antigen and dsRNA alone without the submicron oil-in-water emulsion.
A composition comprising:
- (1) a dsRNA, wherein the dsRNA is polyriboinosinic-polyribocytidylic acid (poly[rI-rC]), polyriboguanylic-polyribocytidylic acid (poly[rG-rC]) or polyriboadenylic-polyribouridylic acid (poly[rA-rU]);
- (2) a submicron oil-in-water emulsion, wherein the submicron oil-in-water emulsion comprises (a) a metabolizable oil, wherein the oil is present in an amount of 0.5% to 20% of the total volume and (b) an emulsifying agent, wherein the emulsifying agent is 0.01% to 2.5% by weight (w/v), and wherein the oil and the emulsifying agent are present in the form of an oil-in-water emulsion having oil droplets substantially all of which are about 100 nm to less than 1 micron in diameter;
- and
- (3) a selected antigen, wherein the selected antigen is an HCV, HIV or a meningococcal antigen,
- and wherein the composition is capable of increasing the immune response to the antigen as compared to delivery of the antigen alone, without the dsRNA and/or the submicron oil-in-water emulsion.
A composition comprising:
- (1) polyriboinosinic-polyribocytidylic acid (poly[rI-rC]);
- (2) a submicron oil-in-water emulsion, wherein the submicron oil-in-water emulsion comprises (a) a metabolizable oil, wherein the oil is present in an amount of 0.5% to 20% of the total volume and (b) an emulsifying agent, wherein the emulsifying agent is 0.01% to 2.5% by weight (w/v), and wherein the oil and the emulsifying agent are present in the form of an oil-in-water emulsion having oil droplets substantially all of which are about 100 nm to less than 1 micron in diameter;
- (3) a CpG oligonucleotide;
- and
- (4) an HCV antigen, an HIV antigen or a meningococcal protein,
- and wherein the composition is capable of increasing the immune response to the antigen as compared to delivery of the antigen alone, without the dsRNA, the submicron oil-in-water emulsion and/or the CpG oligonucleotide.
A composition comprising:
- (1) dsRNA, wherein the dsRNA is polyriboinosinic-polyribocytidylic acid (poly[rI-rC]), polyriboguanylic-polyribocytidylic acid (poly[rG-rC]) or polyriboadenylic-polyribouridylic acid (poly[rA-rU]);
- and (2) a selected antigen, wherein said selected antigen is an HCV antigen, an HIV antigen or a meningococcal protein,
- wherein said dsRNA and/or said selected antigen are adsorbed to a microparticle, and further wherein the composition is capable of increasing the immune response to the selected antigen as compared to delivery of the antigen alone without the dsRNA and/or the microparticle.
A method of making a composition comprising combining a type 1 interferon inducer with an antigen delivery system and/or an immunostimulatory molecule.
Dependencies are inferred from the claim text.